CPX
DAWN

Canaan Partners XI’s Day One Biopharmaceuticals DAWN Stock Holding History

Canaan Partners XI’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Hold
0
– – – 4
2023
Q4 		– Sell
-2,491,561
Closed -$30.2M – 4
2023
Q3 		$30.6M Sell
2,491,561
-56,842
-2% -$741K 26.81% 2
2023
Q2 		$30.4M Hold
2,548,403
– – 21.55% 2
2023
Q1 		$34.1M Hold
2,548,403
– – 24.51% 2
2022
Q4 		$54.8M Sell
2,548,403
-4,415,898
-63% -$90.6M 43.06% 1
2022
Q3 		$139M Sell
6,964,301
-2,699,344
-28% -$57.4M 56.26% 1
2022
Q2 		$173M Hold
9,663,645
– – 61.6% 1
2022
Q1 		$95.9M Hold
9,663,645
– – 39.92% 1
2021
Q4 		$163M Buy
+9,663,645
New +$199M 41.94% 1

Other funds holding DAWN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return